glucose, (beta-d)-isomer has been researched along with Weight Reduction in 118 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.85) | 18.2507 |
| 2000's | 5 (4.24) | 29.6817 |
| 2010's | 93 (78.81) | 24.3611 |
| 2020's | 19 (16.10) | 2.80 |
| Authors | Studies |
|---|---|
| Crisafulli, C; Cuzzocrea, S; Di Bella, P; Di Paola, R; Esposito, E; Genovese, T; Mazzon, E; Meli, R; Menegazzi, M; Muià, C; Suzuki, H | 1 |
| Dinarello, CA; Fantuzzi, G | 1 |
| Behuliak, M; Hojná, S; Hüttl, M; Kadlecová, M; Kujal, P; Malínská, H; Marková, I; Miklánková, D; Neckář, J; Papoušek, F; Rauchová, H; Vaněčková, I; Vaňourková, Z; Zicha, J | 1 |
| Han, Y; He, SM; Wang, DD; Wang, TY; Wang, YM | 1 |
| Barkhof, F; IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Schrantee, A; van Bloemendaal, L; van Ruiten, CC; Veltman, DJ | 1 |
| Bodicoat, DH; Chatterjee, S; Davies, MJ; Edwardson, CL; Gray, LJ; Khunti, K; King, JA; Poulin, B; Redman, EL; Sargeant, JA; Stensel, DJ; Waheed, G; Waller, HL; Webb, DR; Wilding, JPH; Willis, SA; Yates, T | 1 |
| IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Ten Kulve, JS; van Ruiten, CC; Veltman, DJ; Wijdeveld, M | 1 |
| IJzerman, RG; Nieuwdorp, M; van Ruiten, CC; Veltman, DJ | 1 |
| Ananicheva, N; Andreev, D; Bogdanova, A; Charaya, K; Dyachuk, I; Kuzub, A; Mesitskaya, D; Poltavskaya, M; Shchekochikhin, D; Tarasenko, S | 1 |
| Huh, Y; Kim, YS | 1 |
| Ali, SN; Dang-Tan, T; Ericsson, Å; Hansen, BB; Hunt, B; Kallenbach, K; Malkin, SJP; Valentine, WJ | 1 |
| Fuchigami, A; Higa, M; Hirose, T; Hiyoshi, T; Ichijo, T; Inoue, I; Iso, K; Kitazawa, T; Kumashiro, N; Okada, Y; Shigiyama, F; Yoshii, H | 1 |
| Fujii, S; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Koshida, R; Kurihara, Y; Senda, M; Tamura, M; Utsunomiya, K | 1 |
| Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C | 1 |
| Miyauchi, T | 1 |
| Dias, DA; Gill, H; Hung, A; Lenon, GB; Li, M; Luo, S; Nguyen, LT | 1 |
| Badakhshi, Y; Brubaker, PL; Jin, T; Ling, W; Ning, H; Shao, W; Song, Z; Tian, L; Yang, BB | 1 |
| Ayers, CR; de Albuquerque Rocha, N; Hughes, C; Jin, ES; Malloy, CR; Neeland, IJ | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kurihara, Y; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takase, T; Taneda, S; Yamamoto, K | 1 |
| Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
| Fujihara, K; Kaku, K; Matsubayashi, Y; Oe, M; Sato, T; Sone, H; Suganami, H; Tanaka, S; Yaguchi, Y; Yamada, T; Yoshida, A | 1 |
| Bellanger, D; Chappell, N; Elkind-Hirsch, KE; Seidemann, E; Storment, J | 1 |
| Eriksson, JW; Johnsson, E; Katsogiannos, P; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Amino, N; Hayashizaki, Y; Hirosumi, J; Kurosaki, E; Minoura, H; Takakura, S; Takasu, T | 1 |
| Bailey, C; Blak, B; Emmas, C; Kok, M; Rigney, U; Wilding, J | 1 |
| Black, RL; Irons, BK; Minze, MG; Terrell, BT; Will, KJ | 1 |
| Broedl, UC; Cherney, DZI; Cooper, ME; Johansen, OE; Lund, SS; Pfarr, E; Tikkanen, I; Woerle, HJ | 1 |
| Aita, Y; Iwasaki, H; Izumida, Y; Kadowaki, T; Kawakami, Y; Kobayashi, K; Kubota, M; Li, E; Masuda, Y; Matsuzaka, T; Murayama, Y; Nakagawa, Y; Nishi-Tatsumi, M; Piao, X; Sawada, Y; Sekiya, M; Shikama, A; Shimano, H; Sugano, Y; Suzuki, H; Takeuchi, Y; Wada, N; Yagyu, H; Yahagi, N; Yatoh, S | 1 |
| Matsuba, I; Matsuba, R; Nagai, Y; Shimokawa, M; Tanaka, Y | 1 |
| George, J; Hanafusa, T; Lee, G; Marquard, J; Sarashina, A; Shiki, K; Shimada, A; Soleymanlou, N; Taneda, Y; Yasui, A | 1 |
| Forest, CP; Tat, V | 1 |
| Inzucchi, SE; Lupsa, BC | 1 |
| Cherney, DZI; Thomas, MC | 1 |
| Dandona, P; Hansen, L; Langkilde, AM; Mathieu, C; Phillip, M; Thorén, F; Tschöpe, D; Xu, J | 1 |
| Dong, P; Liu, H; Zhao, D | 1 |
| Ares, J; Delgado, E; Maciá, C; Menéndez, E; Pujante, P; Rodriguez Escobedo, R | 1 |
| Hara, K; Hirota, Y; Kishi, M; Komada, H; Kuroki, Y; Matsuda, T; Miura, H; Ogawa, W; Ohara, T; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Takeda, A; Tamori, Y; Yamada, T; Yokota, K | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K; Uno, S | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kato, K; Kishi, H; Maejima, Y; Sakurai, S; Shimizu, M; Shimomura, K; Usui, I | 1 |
| Abe, T; Fujihara, K; Ishizawa, M; Kaku, K; Matsubayashi, Y; Nojima, T; Sone, H; Suganami, H; Tanaka, S; Yoshida, A | 1 |
| Pinto Pereira, L; Rambaran, K; Teelucksingh, S | 1 |
| de Zeeuw, D; Lambers Heerspink, HJ; Leslie, B; List, J; Wie, L | 1 |
| Bello, NT; Verpeut, JL; Walters, AL | 1 |
| Broedl, UC; Jones, R; Kovacs, CS; Rattunde, H; Seshiah, V; Swallow, R; Woerle, HJ | 1 |
| Bolinder, J; Johansson, L; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sjöström, CD; Sugg, J; Wilding, J | 1 |
| Parikh, S; Rohwedder, K; Sugg, J; Wilding, JP; Woo, V | 1 |
| Bilo, HJ; Drion, I; Goudswaard, AN; Holleman, F; Kleefstra, N; van Hateren, KJ | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP | 1 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| le Roux, CW; Miras, AD | 1 |
| Ledford, H | 1 |
| Grandy, S; Hashemi, M; Langkilde, AM; Parikh, S; Sjöström, CD | 1 |
| García, SD; Sanz, AD; Sanz, SD | 1 |
| Albarrán, OG; Ampudia-Blasco, FJ | 1 |
| Hayashizaki, Y; Kihara, R; Kurosaki, E; Li, Q; Mitsuoka, K; Miyoshi, S; Muramatsu, Y; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Uchiyama, Y; Yokono, M | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Athanasiadou, E; Bekiari, E; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Sarigianni, M; Tsapas, A | 1 |
| Inoue, S; Kaku, K; Kiyosue, A; Langkilde, AM; Tokudome, T; Ueda, N; Yang, J | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ | 1 |
| Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS | 1 |
| Broedl, UC; Haneda, M; Inagaki, N; Kadowaki, T; Koiwai, K; Rattunde, H; Taniguchi, A; Terauchi, Y; Woerle, HJ | 1 |
| Adam, G; Berthiller, F; Hennig-Pauka, I; Moll, WD; Nagl, V; Schwartz-Zimmermann, HE; Woechtl, B | 1 |
| Angelopoulos, TP; Doupis, J | 1 |
| Inagaki, N; Kondo, K; Kuki, H; Susuta, Y; Takahashi, N; Yoshinari, T | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Dobbins, R; Dorey, DJ; Kler, L; Lorimer, JD; O'Connor-Semmes, R; Sykes, AP; Walker, S; Wilkison, WO | 1 |
| Almond, SR; Dobbins, R; Kemp, GL; Kler, L; O'Connor-Semmes, R; Sykes, AP; Walker, S; Wilkison, WO | 1 |
| Broedl, UC; Green, A; Narko, K; Salsali, A; Tikkanen, I; Woerle, HJ; Zeller, C | 1 |
| Mediavilla Bravo, JJ | 1 |
| Ishikawa, H; Kashiwagi, A; Kazuta, K; Takahashi, H; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Alba, M; Capuano, G; de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Vercruysse, F; Ways, K | 1 |
| Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Mikhail, N | 1 |
| Cornell, S | 1 |
| Blevins, T | 1 |
| Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R | 1 |
| Hashemi, M; Johnsson, E; Ptaszynska, A; Sjöström, CD; Sugg, J | 1 |
| Pickl, S | 1 |
| Broedl, UC; Jelaska, A; Kim, G; Rosenstock, J; Woerle, HJ; Zeller, C | 1 |
| Banks, P; Bode, BW; Buse, JB; Cefalu, WT; Garg, SK; Heptulla, R; Lapuerta, P; Rendell, M; Rosenstock, J; Sands, AT; Strumph, P; Zambrowicz, BP | 1 |
| Broedl, UC; Cescutti, J; Eilbracht, J; Famulla, S; Johansen, OE; Kaspers, S; Pieber, TR; Soleymanlou, N; Woerle, HJ | 1 |
| Crowe, S; Ferrannini, E; Ferrannini, G; Hach, T; Hall, KD; Sanghvi, A | 1 |
| Fath, R | 1 |
| Abbas, A; Bustamante, M; Farah, Z; Gosavi, S; Mukherjee, D; Said, S; Shami, W; Syed, SH; Teleb, M | 1 |
| Broedl, UC; Christiansen, AV; Kim, G; Merker, L; Roden, M; Roux, F; Salsali, A; Stella, P; Woerle, HJ | 1 |
| Chilton, R; Johansen, OE; Tikkanen, I | 1 |
| Demirci-Tansel, C; Gurel-Gurevin, E; Mericli, F; Ustunova, S; Yazici-Tutunis, S | 1 |
| Broedl, UC; Chilton, R; Crowe, S; Johansen, OE; Lund, SS; McGuire, DK; Neeland, IJ; Woerle, HJ | 1 |
| Shyangdan, DS; Uthman, OA; Waugh, N | 1 |
| Isogawa, A; Ohki, T; Tagawa, K; Toda, N | 1 |
| Furuke, S; Kanno, K; Komiya, C; Miyachi, Y; Ogawa, Y; Shiba, K; Shimazu, N; Tsuchiya, K; Yamaguchi, S | 1 |
| Davies, MJ; Htike, ZZ; Khunti, K; Webb, DR; Youssef, D; Zaccardi, F | 1 |
| Laubner, K; Seufert, J | 1 |
| Amini, S; Eriksson, JW; Johnsson, E; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Aronne, LJ; Mauer, EA; Rathi, S; Shukla, AP; Thomas, CE | 1 |
| Cui, W; Li, D; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
| Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA | 1 |
| González-Ortiz, M; Martínez-Abundis, E; Méndez-Del Villar, M; Ramírez-Rodríguez, AM | 1 |
| Almodóvar-Ruiz, F; Feo-Ortega, G; Gorgojo-Martínez, JJ; Sanz-Velasco, A; Serrano-Moreno, C | 1 |
| Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Tonneijck, L; van Bommel, EJM; van Raalte, DH | 1 |
| Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V | 1 |
| Feng, Y; Kasichayanula, S; List, J; Pfister, M; Zhang, L | 1 |
| Gao, J; Huang, Y; Huang, Z; Li, J; Li, P; Liu, Y; Shao, X; Wu, Q; Xu, D | 1 |
| Cullen, MJ; Devenny, JJ; Godonis, HE; Harvey, SJ; Pelleymounter, MA; Rooney, S | 1 |
| Pahor, A; Parikh, S; Rohwedder, K; Soler, NG; Sugg, J; Wilding, JP; Woo, V | 1 |
| Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y | 1 |
| Bailey, CJ; Iqbal, N; List, JF; T'joen, C | 1 |
| Arguiri, E; Cengel, KA; Christofidou-Solomidou, M; Dukes, F; Grieshaber, PA; Pietrofesa, R; Solomides, CC; Turowski, J; Tyagi, S | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Kim, KA; Meininger, G; Stenlöf, K; Tong, C; Usiskin, K | 1 |
| Ferrannini, E; Hantel, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ | 1 |
| Allison, DB; Baker, BA; Coffey, CS; Steiner, D | 1 |
| Boozer, CN; Herron, AJ | 1 |
| Balan, K; Dunger, N; Falk, W; Hausmann, M; Herfarth, H; Menzel, K; Obermeier, F; Paper, DH; Rogler, G; Schoelmerich, J | 1 |
22 review(s) available for glucose, (beta-d)-isomer and Weight Reduction
| Article | Year |
|---|---|
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
The role of SGLT2 inhibitors in managing type 2 diabetes.
Topics: Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Topics: Adiposity; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Weight Loss | 2019 |
[SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Netherlands; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2013 |
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Topics: Anti-Obesity Agents; Bariatric Surgery; Benzazepines; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Female; Fructose; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Homeostasis; Humans; Islet Amyloid Polypeptide; Lactones; Male; Minimally Invasive Surgical Procedures; Obesity, Morbid; Orlistat; Phentermine; Receptors, Glucagon; Topiramate; Treatment Outcome; Weight Loss | 2014 |
[Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
Topics: Bariatric Surgery; Benzhydryl Compounds; Causality; Comorbidity; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Disease Management; Evidence-Based Medicine; Exercise Therapy; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Obesity; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2013 |
[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Biological Transport, Active; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2013 |
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Odds Ratio; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2015 |
Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss | 2015 |
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2015 |
Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss | 2015 |
A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; United States; Weight Loss | 2015 |
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diuretics; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Weight Loss | 2016 |
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss | 2016 |
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Topics: B-Cell Activating Factor; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Network Meta-Analysis; Odds Ratio; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2016 |
[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome; Weight Loss | 2016 |
Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Odds Ratio; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2017 |
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Lipid Metabolism; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2017 |
56 trial(s) available for glucose, (beta-d)-isomer and Weight Reduction
| Article | Year |
|---|---|
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Brain; Cues; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Appetite; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Ghrelin; Glucagon-Like Peptide 1; Glucose; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Overweight; Peptide YY; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Obesity; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
Topics: Benzhydryl Compounds; Brain; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.
Topics: Benzhydryl Compounds; Diuretics; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Pilot Projects; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Ventricular Function, Left; Weight Loss | 2022 |
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Weight Loss | 2020 |
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Mexico; Middle Aged; Obesity, Morbid; Prediabetic State; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Waist Circumference; Weight Loss; Young Adult | 2020 |
Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.
Topics: Adipose Tissue; Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gluconeogenesis; Glucosides; Glycerol; Humans; Intra-Abdominal Fat; Liver; Male; Middle Aged; Obesity; Placebos; Weight Loss | 2020 |
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Triglycerides; Waist Circumference; Weight Loss | 2021 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Phentermine; Polycystic Ovary Syndrome; Prospective Studies; Single-Blind Method; Topiramate; Treatment Outcome; Weight Loss; Young Adult | 2021 |
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Ghrelin; Glucosides; Humans; Hypoglycemic Agents; Male; Membrane Transport Modulators; Middle Aged; Obesity; Peptides; Prediabetic State; Proof of Concept Study; Risk Factors; Sodium-Glucose Transport Proteins; Sweden; Venoms; Weight Loss | 2017 |
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Electric Impedance; Glucose Clamp Technique; Glucosides; Glycated Hemoglobin; Hyperglycemia; Hypoglycemia; Insulin Resistance; Overweight; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult | 2018 |
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Placebos; Treatment Outcome; Weight Loss | 2018 |
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; gamma-Glutamyltransferase; Glucosides; Hepatitis; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Fat; Weight Loss | 2019 |
Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
Topics: Adipose Tissue; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Lipolysis; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2019 |
Sodium-glucose cotransporter 2 inhibition as a potential treatment for idiopathic oedema.
Topics: Anxiety; Autonomic Nervous System; Benzhydryl Compounds; Blood Pressure; Cross-Over Studies; Edema; Electrolytes; Female; Glucose Intolerance; Glucosides; Hemodynamics; Humans; Models, Theoretical; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2019 |
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2013 |
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2014 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2013 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Risk Assessment; Surveys and Questionnaires; Treatment Outcome; Weight Loss | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
Topics: Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Fasting; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss | 2014 |
Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Treatment Outcome; Weight Loss | 2014 |
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Ketone Bodies; Lipids; Male; Middle Aged; Thiophenes; Treatment Outcome; Weight Loss | 2014 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Hypoglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Membrane Transport Modulators; Middle Aged; Patient Dropouts; Pioglitazone; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss | 2015 |
Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Membrane Transport Modulators; Middle Aged; Patient Dropouts; Pioglitazone; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss | 2015 |
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Weight Loss | 2015 |
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Insulin; Male; Middle Aged; Mycoses; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2015 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; United Kingdom; Weight Loss | 2015 |
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Detemir; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2015 |
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult | 2015 |
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
Topics: Adult; Austria; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss | 2015 |
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
Topics: Adiposity; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Weight Loss | 2016 |
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glucose Intolerance; Glucosides; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Obesity; Peptides; Prediabetic State; Treatment Outcome; Venoms; Weight Loss | 2017 |
Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipids; Male; Metabolic Syndrome; Middle Aged; Weight Loss | 2018 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sodium-Glucose Transport Proteins; Weight Loss; Young Adult | 2009 |
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Weight Loss | 2010 |
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
Topics: Benzhydryl Compounds; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; India; Male; Mexico; Middle Aged; Puerto Rico; Russia; South Africa; Treatment Outcome; United States; Weight Loss | 2012 |
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triglycerides; Weight Loss | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nasopharyngitis; Republic of Korea; Russia; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Thirst; Treatment Outcome; Ukraine; Urination Disorders; Weight Loss | 2013 |
A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment.
Topics: Adult; Anti-Obesity Agents; Benzyl Alcohols; Body Mass Index; Caffeine; Cola; Double-Blind Method; Drug Combinations; Ephedra sinica; Ephedrine; Female; Glucosides; Humans; Logistic Models; Male; Middle Aged; Obesity; Phytotherapy; Plants, Medicinal; Salix; Statistics, Nonparametric; Time Factors; Weight Loss | 2004 |
40 other study(ies) available for glucose, (beta-d)-isomer and Weight Reduction
| Article | Year |
|---|---|
Green tea polyphenol extract attenuates zymosan-induced non-septic shock in mice.
Topics: Animals; Camellia sinensis; Flavonoids; Male; Mice; Phenols; Phytotherapy; Plant Extracts; Polyphenols; Shock; Weight Loss; Zymosan | 2006 |
Stem cell factor-deficient mice have a dysregulation of cytokine production during local inflammation.
Topics: Animals; Ascitic Fluid; Body Weight; Cytokines; Disease Models, Animal; Female; Hypoglycemia; Inflammation; Irritants; Mice; Mice, Mutant Strains; Peritoneal Cavity; Peritonitis; Stem Cell Factor; Turpentine; Weight Loss; Zymosan | 1998 |
Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension.
Topics: Adiposity; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Antioxidants; Benzhydryl Compounds; Blood Pressure; Disease Models, Animal; Energy Metabolism; Glucosides; Hypertension; Male; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Weight Loss | 2021 |
Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients.
Topics: Age Factors; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Retrospective Studies; Weight Loss | 2022 |
Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Metformin; Primary Health Care; Weight Loss | 2022 |
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Topics: Benzhydryl Compounds; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Middle Aged; Sitagliptin Phosphate; United States; Weight Loss | 2019 |
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2020 |
Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction.
Topics: Aged; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Tremor; Valproic Acid; Weight Loss | 2020 |
Inhibitory effect of a weight-loss Chinese herbal formula RCM-107 on pancreatic α-amylase activity: Enzymatic and in silico approaches.
Topics: Animals; Anti-Obesity Agents; Carbohydrate Metabolism; Catechin; Cholestenones; Drugs, Chinese Herbal; Enzyme Assays; Flavanones; Glucosides; Humans; Molecular Docking Simulation; Obesity; Pancreatic alpha-Amylases; Swine; Weight Loss | 2020 |
Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21.
Topics: Animals; Anthocyanins; Diet, High-Fat; Dietary Fats; Fibroblast Growth Factors; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Incretins; Leptin; Liver; Male; Mice; Random Allocation; Weight Gain; Weight Loss | 2020 |
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Pharmaceutical Preparations; Plasma Volume; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2021 |
The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Topics: Absorptiometry, Photon; Adipose Tissue; Animals; Body Composition; Diabetes Mellitus, Type 2; Diet, High-Fat; Eating; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2017 |
Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Practice Patterns, Physicians'; Primary Health Care; Time Factors; Treatment Outcome; United Kingdom; Weight Loss | 2017 |
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2018 |
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Benzhydryl Compounds; Brain; Glucosides; Liver; Male; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vagotomy; Vagus Nerve; Weight Loss | 2017 |
Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2019 |
Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
Topics: Appetite; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Eating; Female; Follow-Up Studies; Ghrelin; Glucosides; Glycated Hemoglobin; Glycemic Index; Humans; Leptin; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabet
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prognosis; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Citrus aurantium and Rhodiola rosea in combination reduce visceral white adipose tissue and increase hypothalamic norepinephrine in a rat model of diet-induced obesity.
Topics: Adipose Tissue, White; Animals; Citrus; Diet, High-Fat; Disaccharides; Dopamine; Glucosides; Hypothalamus; Kaolin; Male; Monoamine Oxidase; Norepinephrine; Obesity; Phenols; Phytotherapy; Plant Extracts; Plant Roots; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Rhodiola; Synephrine; Weight Loss | 2013 |
Dapagliflozin (Forxiga) for type 2 diabetes?
Topics: Adult; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; United Kingdom; Weight Loss | 2013 |
Diabetes drugs ride a bumpy road.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Glucosides; Heart Diseases; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2013 |
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Topics: Adiposity; Animals; Anti-Obesity Agents; Biomarkers; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Fatty Acids; Glucosides; Glycosuria; Hypoglycemic Agents; Lipid Metabolism; Obesity; Oxidation-Reduction; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Up-Regulation; Weight Loss | 2014 |
Metabolism of the masked mycotoxin deoxynivalenol-3-glucoside in pigs.
Topics: Administration, Oral; Animals; Anorexia; Biological Availability; Biotransformation; Chromatography, High Pressure Liquid; Feces; Glucosides; Indicators and Reagents; Injections, Intravenous; Intestinal Absorption; Male; Mass Spectrometry; Mycotoxins; Reproducibility of Results; Swine; Trichothecenes; Vomiting; Weight Loss | 2014 |
[Contributions of SGLT-2 and new drugs under investigation].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Design; Drug Therapy, Combination; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2014 |
Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss | 2015 |
[Weight also counts for patients].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Obesity; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2015 |
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Weight Loss | 2015 |
[Positive experience with SGLT-2 inhibitor in general practice].
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2015 |
Possible effects of Phillyrea latifolia on weight loss in rats fed a high-energy diet.
Topics: Animals; Anti-Obesity Agents; Biomarkers; Blood Glucose; Chlorogenic Acid; Diet, High-Fat; Disease Models, Animal; Energy Intake; Glucosides; Hypoglycemic Agents; Intestine, Small; Lipids; Liver; Luteolin; Male; Obesity; Oleaceae; Phytotherapy; Plant Extracts; Plant Leaves; Plants, Medicinal; Rats, Wistar; Time Factors; Weight Loss | 2016 |
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Incretins; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Topics: Adipose Tissue; Adult; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Epididymis; Glucose; Glucosides; Humans; Hyperphagia; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
Topics: Anti-Obesity Agents; Benzhydryl Compounds; Databases, Factual; Drug Prescriptions; Glucosides; Humans; Hypoglycemic Agents; Obesity; Phentermine; Practice Patterns, Physicians'; Retrospective Studies; United States; Weight Loss | 2016 |
Obesity Week 2016 Annual Meeting.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prediabetic State; Quality of Life; Treatment Outcome; Weight Loss | 2017 |
Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Spain; Time Factors; Treatment Outcome; Weight Loss | 2017 |
Antifibrosis effects of total glucosides of Danggui-Buxue-Tang in a rat model of bleomycin-induced pulmonary fibrosis.
Topics: Animals; Bleomycin; Collagen Type I; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Glucosides; Lung; Male; Phytotherapy; Pulmonary Fibrosis; Random Allocation; Rats; Rats, Wistar; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Weight Loss | 2011 |
Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
Topics: 3-Hydroxybutyric Acid; Animals; Anti-Obesity Agents; Benzhydryl Compounds; Blood Glucose; Caloric Restriction; Diet; Dose-Response Relationship, Drug; Drinking; Energy Intake; Glucosides; Hyperphagia; Insulin; Male; Obesity; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Respiration; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss | 2012 |
Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Radioprotective role in lung of the flaxseed lignan complex enriched in the phenolic secoisolariciresinol diglucoside (SDG).
Topics: Animals; Antioxidants; Butylene Glycols; Dietary Carbohydrates; Eating; Female; Flax; Glucosides; Inflammation; Lignans; Lung; Mice; Mice, Inbred C57BL; Phenols; Radiation Pneumonitis; Radiation-Protective Agents; Survival Analysis; Thorax; Weight Loss | 2012 |
Simmondsin for weight loss in rats.
Topics: Acetonitriles; Animals; Appetite Depressants; Body Composition; Body Weight; Cyclohexanes; Dose-Response Relationship, Drug; Eating; Erythrocytes; Glucosides; Kidney; Leukocytes; Liver; Male; Obesity; Organ Size; Rats; Rats, Sprague-Dawley; Thinness; Weight Loss | 2006 |
In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis.
Topics: Acute Disease; Animals; Antioxidants; Chronic Disease; Colitis; Colon; Cytokines; Dextran Sulfate; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Inflammation Mediators; Intestinal Mucosa; Lymph Nodes; Macrophages; Mice; Mice, Inbred BALB C; Peroxidase; Phenols; Respiratory Burst; Weight Loss | 2007 |